mTOR inhibitor with anti-cancer activity. It has anti-angiogenic effects which may contribute to the antitumor activity of temsirolimus observed in breast cancer. Temsirolimus shows synergistic in vivo anti-myeloma effects in combination with dexamethasone in a xenograft model.